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ABSTRACT 
The avidity of the T cell receptor (TCR) for antigenic peptides presented by the major 
histocompatibility complex (pMHC) on cells is a key parameter for cell-mediated immunity. Yet 
a fundamental feature of most tumor antigen-specific CD8+ T cells is that this avidity is low. In 
this study, we addressed the need to identify and select tumor-specific CD8+ T cells of highest 
avidity, which are of the greatest interest for adoptive cell therapy in cancer patients. To identify 
these rare cells, we developed a peptide-MHC multimer technology, which uses reversible Ni2+-
nitrilotriacetic acid histidine tags (NTAmers). NTAmers are highly stable but upon imidazole 
addition they decay rapidly to pMHC monomers, allowing flow cytometry-based measurements 
of monomeric TCR-pMHC dissociation rates of living CD8+ T cells on a wide avidity spectrum. 
We documented strong correlations between NTAmer kinetic results and those obtained by 
surface plasmon resonance (SPR). Using NTAmers that were deficient for CD8 binding to 
pMHC, we found that CD8 itself stabilized the TCR-pMHC complex, prolonging the 
dissociation half-life several-fold. Notably, our NTAmer technology accurately predicted the 
function of large panels of tumor-specific T cells that were isolated prospectively from cancer 
patients. Overall, our results demonstrated that NTAmers are effective tools to isolate rare high-
avidity cytotoxic T cells from patients for use in adoptive therapies for cancer treatment. 
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INTRODUCTION 
Binding of TCR to peptide-MHC (pMHC) complex is the key step for T cell activation and 
cellular immune responses (1). Efficient triggering of T cell responses critically depends on the 
strength of TCR-mediated antigen recognition, namely it has been shown that strong binding to 
pMHC confers superior effector function than weak interactions (2-7). This is of particular 
interest for immunotherapy based on adoptive T cell transfer, aiming to convey immune 
reactivity against tumor-associated antigens, for which endogenous T cell responses are usually 
weak. Many tumor antigens are in fact self-antigens that are expressed in the thymus, and 
accordingly, most tumor-reactive T cells of high avidity become negatively selected, in contrast 
to pathogen-specific T cells (8). Therefore, there is a need for a robust technology that allows 
rapid identification and isolation of CD8+ T cells expressing TCRs capable to efficiently activate 
and enhance T cell function against malignant cells. 
TCR-pMHC binding parameters are typically assessed by SPR, which requires laborious and 
expensive production of soluble TCRs and ignores the TCR-pMHC avidity effects related to 
CD8 co-receptor binding. On the other hand, kinetic measurements using pMHC tetramers or 
multimers have been extensively studied on the surface of antigen-specific CD8+ T cells, but due 
to the multivalent and heterogeneous composition of these multimers, this approach does not 
allow to accurately determine TCR-pMHC dissociation rates (9). Binding and dissociation 
measurements should ideally be performed using monomeric pMHC complexes. Because TCR-
pMHC interactions typically exhibit weak affinities and fast dissociation rates, this has long 
precluded conclusive measurements with monomeric pMHCs (10).  
Nauerth et al. (11) recently measured monomeric TCR-pMHC dissociation kinetics using 
reversible Streptamers and reported that virus-specific CD8+ T cells with longer half-lives (low 
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koff rates) conferred increased functional avidity and better in vivo protection than T cells 
exhibiting shorter t1/2 (high koff rates). However, the Streptamer assay (11) needs a significant 
lag time until monomeric TCR-pMHC dissociation starts to become detectable, limiting thereby 
off-rate analyses to antigen-specific T cells of relative long half-lives, typically found in immune 
responses against pathogens. Moreover, accurate measurements of TCR-pMHC binding 
parameters on living T cells (11-14) require specialized equipment, which is currently not 
available for the high-throughput screen of antigen-specific T cell populations. 
To overcome these limitations, we here applied pMHC multimers built on reversible chelate 
complexes of Ni2+-nitriloacetic acid (NTA) with oligohistidines (15) allowing the efficient and 
direct cytometry-based assessment of monomeric TCR-pMHC dissociation kinetics on the 
surface of (self) tumor-specific CD8+ T cells. We found that the NTAmer technology accurately 
predicted T cell biological responses within a large panel of tumor-specific T cell clones, 
providing novel means for the direct isolation of rare functionally relevant CD8+ T cells for 
adoptive cell transfer therapy.   
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MATERIALS AND METHODS 
Ethics statement 
The three HLA-A*0201-positive patients had stage III/IV metastatic melanoma and were included 
in immunotherapy studies (patient LAU 50, NCT00112242; patient LAU 155, NCT00002669; and 
patient LAU 618, NCT00112229; www.clinicaltrials.gov). The studies were designed and 
conducted according to the relevant regulatory standards, upon approval by the ethical commissions 
and regulatory agency of Switzerland. Patient recruitment, study procedures, and blood withdrawal 
were done upon written informed consent. 
Primary bulk CD8+ T cells and generation of tumor-specific CD8+ T cell clones  
Human primary HLA-A*0201pos CD8+ T lymphocytes were obtained following positive 
enrichment using anti-CD8-coated magnetic microbeads (Miltenyi Biotec), and cultured in 
RPMI supplemented with 8% human serum (HS) and 150 U/ml recombinant human IL-2. HLA-
A*0201-NTAmerpos (NY-ESO-1157-165 -specific or Melan-AMART-1-26-35 -specific) T cells from 
melanoma patient LAU 50 and LAU 618, respectively, were sorted by flow cytometry, cloned by 
limiting dilution and expanded in RPMI 1640 medium supplemented with 8% HS, 150 U/ml 
recombinant human IL-2, 1 µg/ml phytohemagglutinin (PHA) (Oxoid) and irradiated (30 Gy) 
allogeneic PBMCs as feeder cells. For patient LAU 155, twenty HLA-A*0201/NY-ESO-1157-165 
-specific T cell clones expressing dominant TCR BV1, BV8 and BV13 clonotypes and a non-
dominant TCR BV2 clonotype were selected from our previously generated database of T cell 
clones (16), thawed and in vitro expanded before further use. Primary bulk CD8+ T cells and 
tumor-specific T cell clones were expanded by periodic restimulation with 30-Gy irradiated 
allogeneic PBMCs and 1 µg/ml PHA. 
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Lentiviral production and cell transduction 
Full-length codon-optimized TCR AV23.1 and TCR BV13.1 chain sequences of a dominant HLA-
A*0201/NY-ESO-1157–165 specific T cell clone of patient LAU 155 (16) were cloned in the pRRL 
third generation lentiviral vectors as an hPGK-AV23.1-IRES-BV13.1 construct  and structure-based 
amino acid substitutions were introduced into the WT TCR sequence as described previously (5). 
Lentiviral production was performed using the calcium-phosphate method and concentrated 
supernatant of lentiviral-transfected 293T cells was used to infect TCR-α knockout CD8+ SUP-T1 
cells (ATCC number CRL-1942, mycoplasma-free), CD8-null Jurkat T cells (ATCC number TIB-
152; mycoplasma-free), or primary CD8+ T cells overnight. Levels of transduced TCR expression 
on SUP-T1, Jurkat cells and primary bulk CD8+ T cells were monitored with PE-labeled HLA-
A*0201/NY-ESO-1157-165 specific multimers (TCMetrix Sàrl) and FITC-conjugated BV13.1 
antibody (Beckman Coulter). 
NTAmer production and staining 
NTAmers were synthetized by TCMetrix Sàrl (www.tcmetrix.ch) as described in (15). NTAmers 
are composed of Streptavidin-Phycoerythrin (SA-PE, Invitrogen) complexed with biotinylated 
peptides carrying four Ni2+-nitrilotriacetic acid (NTA4) moieties and non-covalently bound to His-
tagged HLA-A*0201 monomers containing β2m or a Cy5-labeled β2m. Monomers were obtained 
by refolding of the HLA-A*0201 heavy chain in the presence of β2m or Cy5-labeled β2m 
containing the S88C mutation with Cy-5-maleimide (GE Healthcare) and the analog NY-ESO-1157-
165 [SLLMWITQA] or Melan-AMART-126-35 [ELAGIGILTV] tumor antigenic peptide, optimized for 
enhanced HLA-A*0201 binding. After purification on a Superdex S75 column, pMHC monomers 
were mixed at a 10-fold ratio with SA-PE-NTA4 in the presence of Ni2+ as described in (15). The 
same procedure was used to prepare CD8-binding deficient HLA-A*0201 monomers bearing the 
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D227K/T228A mutations in the HLA-α3 domain (17). Dually labeled NTAmers containing SA-PE 
and Cy5-labeled monomers were used for dissociation kinetic measurements as described below. 
Single labeled NTAmers containing SA-PE and unlabeled monomers were used for flow cytometry-
based sorting of tumor-specific T cells. Once sorted, tumor-specific T cells were treated with 100 
mM imidazole at 4oC, allowing the rapid dissociation of the SA-PE-NTA4 scaffold and pMHC 
monomers before in vitro T cell cloning by limiting dilution.     
Dissociation kinetic measurements 
TCR-transduced CD8+ SUP-T1 or CD8- Jurkat cells (5x105 cells) and tumor-specific CD8+ T cell 
clones (2x105 cells) derived from patients LAU 155, LAU 50 and LAU 618 were incubated for 40 
min at 4°C with HLA-A*0201/NY-ESO-1157-165 or HLA-A*0201/ Melan-AMART-126-35 NTAmers 
containing streptavidin (SA)-phycoerythrin (PE) and Cy5-labeled monomers in 50 μl FACS buffer 
(PBS supplemented with 0.5% BSA, 15 mM HEPES and 0.02% NaN3). After a washing step, cells 
were suspended in 500 µl FACS buffer at 15°C (for SUP-T1 and Jurkat cells) or 200 µl FACS 
buffer at 4°C (for primary T cell clones from melanoma patients) and cell surface-associated mean 
fluorescence was measured under constant temperature using a thermostat device (15oC for SUP-T1 
and Jurkat cells and 4oC for primary T cell clones) on a SORP-LSR II flow cytometer (BD 
Biosciences) following gating on living cells. PE-NTA4 and Cy5-pMHC monomer fluorescence 
was measured before (between 30s to 1 min; baseline) and during 5 to 10 minutes after the addition 
of imidazole (100 mM). High-resolution microscopy flow analysis was performed on an Amnis 
ImageStreamx Mark II instrument (Merck Millipore) using a 40x objective. Staining was performed 
as described above for SUP-T1 cells. PE-NTA4 and Cy5-pMHC monomer fluorescence was 
measured before (t = 0) and during 5 minutes upon the addition of imidazole (100 mM) at 20oC.  A 
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60 seconds lag time due to the automated handling of cell suspension by the Amnis instrument 
precluded earlier time-point measurements.  
Dissociation kinetic data analysis 
Flow cytometry-based data were processed using the FlowJo software (v.9.6, Tree Star, Inc.). After 
gating on living cells, PE or Cy5 mean fluorescence intensity was derived using the kinetic module 
of the FlowJo software. Gates of 6 seconds period were created following addition of imidazole at 
the following time-points; 15s, 30s, 45s, 60s, 90s, 120s and then every minute for 10 minutes. 
Geometric MFI was measured at each time-points after gating on HLA-A*0201/NY-ESO-1157-165- 
or HLA-A*0201/ Melan-AMART-126-35-specific staining. Irrelevant Flu-specific gMFI values were 
systematically subtracted at the various time-points. Corrected gMFI values were plotted and 
analyzed using the GraphPad Prism software (v.6, GraphPad). 
Calcium mobilization assays 
5×104 TCR- transduced SUP-T1 or primary bulk CD8+ T cells were loaded with 2 μM Indo 1-
AM (Sigma-Aldrich, Switzerland) for 45 minutes at 37°C. Cells were washed and resuspended 
in 250 μl pre-warmed RPMI containing 2% FCS. Baseline was recorded for 30 seconds before 1 
μg/ml of undissociated HLA-A*0201/NY-ESO-1157-165 NTAmers (for SUP-T1) or 1 μg/ml 
HLA-A*0201/NY-ESO-1157-165-specific multimers (for primary CD8+ T cells) were added to the 
cells allowing specific stimulation. Intracellular Ca2+ flux was assessed over 5 minutes under UV 
excitation and constant temperature of 37°C using a thermostat device on a LSR II SORP (BD 
Biosciences) flow cytometer. Indo-1 (violet)/Indo-1 (blue) 405/525 nm emission ratio was 
analyzed by FlowJo kinetics module software (TreeStar). 
Chromium release and tumor recognition assays  
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The functional avidity of antigen recognition was analyzed in a 4-hour 51Cr-release assay using 
TAP-/- deficient T2 (HLA-A*0201pos) target cells pulsed with serial dilutions of the natural NY–
ESO-1157-165 peptide [SLLMWITQC] for tumor-specific T cell clones derived from patient LAU 
155 and LAU 50 or the natural Melan-AMART-126-35 peptide [EAAGIGILTV] for tumor-specific T 
cell clones derived from patient LAU 618. The NY-ESO-1 peptide was preincubated for 1 hour 
at room temperature with the disulfide-reducing agent Tris [2-carboxyethyl] phosphine (TCEP; 2 
mM, Pierce Biotechnology) before functional assays. The percentage of specific lysis was 
calculated as follows: 100 × (experimental − spontaneous release)/ (total − spontaneous release). 
For T cell clones of defined TCR αβ clonotypes previously derived from patient LAU 155 (16),  
antigen-specific recognition and lytic activity was further assessed against the melanoma cell 
lines Me 275 (HLA-A2pos/NY-ESO-1pos) and NA8 (HLA-A2pos/NY-ESO-1neg).  
Statistics 
Statistical analyses were done with the GraphPad Prism software. A minimum of three 
independent experiments were performed to ensure a statistical power of 100% at α = 0.05 (Fig. 
2 and 3), and a sample size ≥ 23 to ensure a statistical power of 80% at α = 0.05 (Fig. 5). 
Correlation analyses were performed using Pearson (Fig. 2 to 4) or Spearman (Fig. 5) coefficient 
r. The associated p value (two-tailed, α = 0.05) quantifies the likelihood that the correlation is 
due to random sampling. Two different investigators performed each TCR-pMHC dissociation 
kinetic experiment independently, and experiments described in Figure 5 were performed 
blinded for both sample allocation and outcome assessment.  
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RESULTS 
Direct measurements of monomeric TCR-pMHC dissociation kinetics by NTAmers 
We previously developed a method for the isolation and analysis of antigen-specific cytotoxic T 
cells by reversible NTAmers (10, 15). Upon addition of imidazole at low, non-toxic 
concentration, the SA-PE-NTA4 moieties rapidly decay (average dissociation half-life of 2.5 
sec), thereby releasing the pMHC monomers bound at the cell surface. Consequently, NTAmers 
allow FACS-sorting of CD8+ T cells without inducing adverse effects on the cell integrity (e.g. 
activation-induced cell death) (10, 15). Taking advantage of the fact that NTAmers can be 
switched from stable binding to rapid dissociation, a two-color NTAmer was engineered to 
assess monomeric TCR-pMHC dissociation kinetics directly on living CD8+ T cells (Fig. 1A).  
We first evaluated this novel approach by direct visualization of the dissociation process on 
individual human CD8+ SUP-T1 cells expressing TCRs of increasing affinities for the HLA-
A*0201-restricted tumor epitope NY-ESO-1157-165 (18), using a flow cytometer generating 
simultaneous high resolution microscopy imaging (ImageStreamX MarkII) (Fig. 1B). As 
predicted, we observed strongest and most sustained fluorescence levels for T cells of very high 
TCR affinities (e.g. QMα and wtc51m). Because of a 60 sec lag time due to the automated 
handling of cells following the addition of imidazole, the imaging approach precluded the 
visualization of labeled monomeric pMHC dissociation for T cells expressing TCRs ranging 
within the physiological range (e.g. V49I, wild-type and DMβ). To solve this issue, we used a 
conventional flow cytometer (LSRII-SORP) equipped with a thermostat, which drastically 
reduced the lagging time to less than 5 sec (Fig. 1C), thereby allowing the accurate assessment of 
monomeric pMHC dissociation kinetics on the surface of CD8+ T cells across a wide TCR 
affinity spectrum (Fig. 1D, Supplementary Fig. S1A). To validate the NTAmer technology, we 
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next compared these dissociation values with SPR kinetics data obtained with the corresponding 
soluble TCRs (Table 1). Robust correlations were found between NTAmer-based cell surface 
monomeric pMHC dissociation kinetics (half-live t1/2 and koff), with both koff rates and affinities 
measured by SPR, contrasting with the weaker correlations obtained with pMHC tetramers (Fig. 
2A, Supplementary Fig. S2A).  
 
CD8 co-receptor stabilized the TCR-pMHC complex by prolonging the dissociation half-life by 
a factor of 3 to 4-fold  
To precisely quantify the contribution of CD8 co-receptor to monomeric TCR-pMHC 
dissociation, we generated NTAmer227-228 variants containing the HLA-A*0201 D227K/T228A 
mutations in the MHC α3 domain that abolish CD8 binding to pMHC (17). Using the same panel 
of TCR transduced CD8+ SUP-T1 cells we show that abrogating CD8-MHC binding drastically 
diminished dissociation half-lives (t1/2) over the whole spectrum of TCR affinities (Fig. 2B, 
Supplementary Fig. S1B and C). Monomeric off-rate (koff and t1/2) correlations between 
NTAmers227-228 and SPR were highly significant (Fig. 2A, Supplementary Fig. S2A). 
Comparison between wild-type and CD8-binding deficient NTAmer-based half-lives revealed 
that CD8 stabilized by a factor of 3 to 4-fold the interaction between tumor-specific TCRs and 
HLA-A*0201/NY-ESO-1 irrespectively of the TCR affinity (Fig. 2B). A similar effect of CD8 
binding to pMHC was observed when using TCR transduced Jurkat T cells that lack CD8 
expression (Fig. 2C and D; Supplementary Fig. S2B) with koff and t1/2 values that were highly 
comparable to those found by NTAmers227-228 or by SPR on CD8+ T cells (Table 1). Altogether, 
the NTAmer technology permits (i) the precise measurements of monomeric TCR-pMHC 
dissociation kinetics directly on living T cells expressing a wide TCR affinity range, including 
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those typically found within the self/tumor-specific repertoires, and (ii) the quantification of the 
contribution of CD8 binding on the TCR-pMHC complex stability, which is not possible in SPR 
measurements.   
 
Monomeric TCR-pMHC dissociation kinetics correlate with enhanced T cell responsiveness   
Next we compared koff rates obtained using NTAmers and the intracellular calcium mobilization 
on CD8+ SUP-T1 cells (Fig. 3A and B) and primary CD8+ T cells (Fig. 3D and E) expressing 
the panel of affinity-optimized TCRs against NY-ESO-1 tumor antigen. In line with our previous 
reports (19, 20), the Ca2+ flux was enhanced with increasing TCR affinity, up to reaching a 
plateau, while further affinity increase (KD < 1 µM) resulted in reduced calcium signaling. 
Within the physiological TCR-pMHC affinity range, however, both SUP-T1 cells and primary T 
cells exhibited strong correlations between dissociation rates and Ca2+ mobilization (Fig. 3C and 
F); there was an enhanced Ca2+ flux in T cells of longer half-lives (low koff), contrasting with the 
reduced signaling observed in T cells of shorter t1/2 (high koff). An overall reduction in Ca2+ flux 
was observed when using mutant multimer/HLA-A*0201227-228 for specific stimulation, but this 
effect was less stringent for T cells expressing very high TCR affinities (e.g. TMα, QMα and 
wtc51m) (Fig. 3A and B). As previously reported (20-22), these data indicate that the degree of 
CD8 dependence for T cell activation inversely depends on the affinity and dissociation half-life 
of the TCR-pMHC interaction. 
We extended these observations to a clinically relevant setting, and characterized koff rates and 
functional avidity of T cells obtained from a large set of HLA-A*0201/NY-ESO-1157-165-specific 
CD8+ T cell clones expressing well-defined TCRαβ clonotypes derived from LAU 155, a 
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melanoma patient with long lasting anti-tumor T cell responses (16). The dissociation rates of 
those cytotoxic T cell clones clustered within a narrow range (Fig. 4A, Supplementary Fig. S3A), 
and strongly correlated with EC50 target cell killing (50% maximal lysis; Fig. 4C) and tumor cell 
recognition (Fig. 4E), with TCR clonotypes having long half-lives (low koff) exhibiting increased 
T cell cytotoxicity (Fig. 4B and D). Conversely, NY-ESO-1-specific TCR clonotypes with short 
half-lives (high koff) showed reduced T cell killing capacities.  
 
Identification of rare high avidity, tumor-specific CD8+ T cells by monomeric TCR-pMHC 
dissociation kinetic measurements 
To find out whether NTAmers allow direct identification of tumor-specific CD8+ T cells with 
high tumor killing capacity, we derived 147 tumor-specific T cell clones from two other 
melanoma patients with detectable ex vivo T cell responses against the HLA-A*0201 restricted 
tumor antigens NY-ESO-1157-165 and Melan-AMART-126-35, respectively, and screened them for 
monomeric dissociation rates (Fig. 5A and D; Supplementary Fig. S3B and C). Tumor-specific T 
cell clones were distributed according to their TCR Vβ family expression using monoclonal 
antibodies and koff rate analyses revealed large differences in half-lives between specific TCRs 
(Supplementary Fig. S4). Next, we performed killing assays with 57 clones selected for 
relatively low or high koff values (Fig. 5B and E). We observed, for both antigenic specificities, a 
robust correlation between off-rates and the functional avidity (EC50) determined with the 
cytotoxicity assay (Fig. 5C and F), demonstrating that NTAmers allow reliable assessment of 
surface-based TCR-pMHC dissociation kinetics and rapid selection of highly potent tumor-
specific T cell clones derived from different cancer patients.  
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DISCUSSION 
Identifying antigen-specific T cells that confer efficient effector function is critical for successful 
adoptive cell therapy. The stability of TCR binding for the peptide-MHC complex is a key 
determinant for T cell activation. Several lines of evidence argue for a close relationship between 
cell surface dissociation kinetics (koff) and functional T cell responses (5, 23-26). Yet, rapid and 
accurate screening methods to measure TCR-pMHC binding kinetics are still needed to isolate 
antigen-specific T-cells expressing TCRs of high binding avidity. Recently, we developed a 
novel approach combining reversible peptide-MHC multimers (NTAmers; (15)) and real-time 
flow cytometry (Fig. 1). Using SPR, we had previously determined the TCR-pMHC binding 
strength of sequence-optimized HLA-A*0201/NY-ESO-1157-165 specific TCRs with increasing 
affinity of up to 150-fold from the wild-type receptor, including two outliers, a very low- and a 
very high-affinity TCR (5, 20). This TCR panel provides a unique model for validating 
monomeric TCR-pMHC dissociation kinetics at the surface of T cells by NTAmers. Here, we 
demonstrate that NTAmer-based off-rates (koff, t1/2) followed the same TCR-pMHC binding 
hierarchy than previously established (20), in excellent agreement to both binding parameters, 
koff and the dissociation constant KD, obtained by SPR (Fig. 2; Table 1). 
Due to their switch ability i.e. high stability and rapid reversibility (< 5 sec), NTAmers allowed 
accurate determination of dissociation rates, even for weak TCR-pMHC interactions, i.e. fast off-
rates, such as those found for (self) tumor-specific CD8+ T cell repertoires (Fig. 4). Notably, the 
NTAmer approach differs from the Streptamer one, which is mostly limited to the detection of 
CD8+ T cells of high avidity such as virus-specific cells, as it requires a significant lag time (60 
sec) before monomeric TCR-pMHC dissociation becomes detectable (11).  Moreover, the 
NTAmer-based assay represents a rapid and straightforward approach for the quantitative 
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assessment of monomeric koff rates on a large set of cloned antigen-specific CD8+ T cells 
derived from different patients and tumor epitopes (HLA-A*0201/NY-ESO-1157-165 and HLA-
A*0201/Melan-AMART-126-35) (Fig. 5). Importantly, we demonstrate robust correlations between 
dissociation off-rates and the biological responses (e.g calcium flux and target cell killing) on a 
large panel of CD8+ T cell clones specific for two distinct tumor antigens, indicating that TCR-
ligand koff rate is a reliable predictor of T cell function (Fig. 3-5).  
Interactions between TCRs and pMHC are usually measured by SPR or pMHC tetramer or 
multimer staining, which requires one binding partner in soluble form. Both approaches have 
caveats. Due to their incomplete dissociation and multivalent nature, accurate off-rates data from 
pMHC tetramer/multimer staining measurements are imprecise. Conversely, monomeric 
dissociation koff rates measured by the NTAmer technology were within the range of seconds to 
minutes, spanning a broad range (2-logs), as compared to a narrow range of minutes observed 
when using pMHC tetramers. Moreover, SPR fails to take into account rapid rebinding of the 
TCR to the same pMHC, because one of the two binding partners is constantly moving in the 
fluid phase, which impacts on the binding kinetics. Increased kon rates have been shown to allow 
rapid rebinding after TCR-ligand dissociation, resulting in enhanced effective dissociation half-
life of the TCR-pMHC interaction (25, 27). This may explain our observation that TCR variants 
with faster kon (e.g. TMα and QMα) showed prolonged NTAmer-based dissociation half-lives 
compared to soluble monomeric off-rates measured by SPR (Table 1, Supplementary Fig. S5). 
The NTAmer-based approach further deviates from SPR measurements, as it provides data on 
living cells and includes contributions of CD8 to TCR-pMHC interactions. The CD8 co-receptor 
enhances antigen recognition and T cell activation by stabilizing TCR-pMHC interaction at the 
cell surface (28-31) and recruiting p56lck to TCR/CD3 complex promoting cell signaling (32, 33). 
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Here we demonstrate that CD8 strengthened the TCR-pMHC binding mainly by decreasing the 
TCR-pMHC dissociation by a factor of 3 to 4-fold (Fig. 2), as anticipated by previous tetramer 
dissociation assays (22, 30). Interestingly, the CD8 stabilization factor was independent of the 
TCR-pMHC affinity, in contrast to the CD8 dependence for T cell activation, which can be 
directly linked to the affinity (3, 20, 22), and allows tuning the sensitivity and specificity of T 
cell responses (34).  
We recently provided new evidence that T cell signaling and activation are optimal within a 
given TCR-pMHC affinity window (20), controlled through TCR affinity-mediated regulatory 
molecules, involving the inhibitory receptor PD-1 and SHP-1 phosphatase (19). Furthermore, 
while high avidity T cells have been shown to control tumor growth, they become preferentially 
tolerized in the tumor microenvironment (35) or can target normal tissues expressing the cognate 
antigen (36, 37). Therefore, tumor-specific T cells of high avidity may not always be 
functionally better, and it remains to be fully determined to which degree intermediate or high 
avidity T cells contribute to protective immunity. In this regard, NTAmers constitute a highly 
valuable tool for assessing the TCR-pMHC avidity and its relation to cell activation, signaling 
and function in naturally- or therapeutically-induced tumor-specific T cell responses, with TCR-
pMHC affinities spanning within the physiological range.  
In summary, NTAmer technology enables efficient and direct interrogation of monomeric TCR-
pMHC dissociation kinetics on a large set of living antigen-specific T cells by flow cytometry, 
and provides novel perspectives for rapid identification of rare functionally relevant tumor-
reactive CD8+ T cells . Our approach may also be applicable to the analysis of other weak 
protein-protein interactions. Precise and wide-spread characterization of TCR-pMHC avidities 
will likely improve the development of T cell based immunotherapies in cancer patients.    
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Table 1. Kinetic characteristics of HLA-A*0201/NY-ESO-1157-165-specific TCR variants 
 
(a) Wild-type TCR (BC1; AV23.1/BV13.1) was isolated from melanoma patient LAU 155 (16) and a panel of TCR variants of 
progressive increasing affinities against HLA-A*0201/NY-ESO-1157-165 was established as described in (20). 
(b) TCR-pMHC affinity, koff and kon values were previously measured by SPR as reported in (20). 
(c) CD8+ T cells, TCR-transduced SUP-T1 cells; CD8- T cells, TCR-transduced Jurkat cells. 
n.a, not applicable; n.d, not done.  
 
 
 
 
 
 
  
 SPR TCR-pMHC kinetics (b) NTAmer dissociation kinetics NTAmer227-228 dissociation kinetics 
 Soluble TCRs CD8+ (c) CD8- (c) CD8+ (c) CD8- (c) 
TCR variants (a) 
KD 
μM 
 
kon 
M-1s-1 
x104 
koff  
s-1 
x10-2 
t1/2  
s 
 
koff 
s-1 
x10-2 
t1/2 
s 
 
koff 
s-1 
x10-2 
t1/2  
s 
 
koff 
s-1 
x10-2 
t1/2 
s 
 
koff  
s-1 
x10-2 
t1/2 
s 
 
V49I n.a n.a n.a n.a 21.21 3 n.a n.a n.a n.a n.a n.a 
Wild-type 21.4 1.1 23.0 3 4.08 17 10.2 7 11.2 6 15.4 5 
G50A  4.62 1.5 6.9 10 1.47 47 n.d n.d 5.28 13 n.d n.d 
A97L  2.69 2.3 6.1 11 1.60 44 n.d n.d 4.70 15 n.d n.d 
DMβ  1.91 2.4 4.5 15 0.78 90 2.76 25 3.02 23 3.15 22 
TMβ  0.91 1.4 1.3 53 0.28 247 1.03 67 0.87 79 0.97 72 
TMα 0.40 12.1 4.8 14 0.44 158 n.d n.d 1.76 40 n.d n.d 
QMα 0.14 10.9 1.5 46 0.21 341 0.80 87 0.74 94 0.75 92 
Wtc51m 0.015 8.5 0.13 533 0.05 1505 0.14 497 0.15 475 0.14 496 
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FIGURE LEGENDS 
Figure 1. Assessment of monomeric dissociation kinetics by reversible NTAmers. (A) Basic 
illustration of the off-rate (koff) dissociation assay. Human CD8+ antigen-specific T cells were 
first stained with HLA-A*0201/tumor antigen-specific NTAmers containing PE-labeled 
backbone (green) and Cy5-labeled monomers (red) carrying imidazole-sensitive Ni2+-NTA4 
moieties. Upon addition of imidazole, the NTAmer multimeric complex rapidly dissociated into 
Cy5-labeled pMHC monomers releasing the SA-PE NTA4 molecules. Decay of Cy5 
fluorescence was visualized by high-resolution microscopy flow cytometry (B) or conventional 
flow cytometry over time (C) using SUP-T1 cells engineered with TCRs of incremental affinity 
for the tumor antigen A2/ NY-ESO-1157-165 (20) (Table 1). (B) Differential interference contrast 
(DIC), PE, Cy5 and PE/Cy5 composite images are shown at the indicated time-points. (C) 
Representative dot plots from FACS-based dissociation curves (Cy5-labeled pMHC monomers) 
from TCR-transduced SUP-T1 cells. Decay of PE-labeled NTA4 scaffold moieties is depicted 
alongside.  (D) Temperature-controlled (15oC) TCR-pMHC monomeric dissociation off-rates 
(Cy5-monomers, blue circles) were assessed upon addition of imidazole (t = 0) within the entire 
panel of TCR-transduced SUP-T1 cells. Data best fitted a one-phase exponential decay equation 
after subtraction of non-specific background and are expressed as % of maximal binding, 
normalized to 100% and plotted over time. Decay of SA-PE-NTA4 fluorescence (white circles) 
from NTAmers occurred within the first 2-3 seconds upon imidazole addition and was 
independent TCR-pMHC affinity. Time for half maximal binding (t1/2) was determined and 
average half-life value (t1/2) of  > 3 independent experiments is depicted in second (s) for each 
TCR engineered SUP-T1 cell variant. Untransduced SUP-T1 cells; no TCR. N/A; not applicable. 
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Figure 2. Contribution of CD8 binding to TCR-pMHC dissociation kinetics. (A) Positive 
correlations (Pearson coefficient r and p value) obtained between surface-based monomeric half-
lives (t1/2) with wild-type NTAmers (monomer, blue line) or CD8-binding deficient NTAmers227-
228 (monomer227-228, red line) on CD8+ TCR-transduced SUP-T1 cells, and monomeric half-lives 
(t1/2) and affinities (equilibrium dissociation constant KD) as measured by SPR on soluble TCRs. 
Weaker correlations were found when assessing half-lives using a pure grade tetramer assay 
(opened circles). (B) Direct comparison of wild-type (blue circles) and CD8-binding deficient 
(red diamonds) monomeric dissociation half-lives by NTAmers (> 3 independent experiments). 
The impact of CD8 binding is shown as fold change (grey histograms) for each TCR-transduced 
SUP-T1 variant. (C) Representative first order monomeric TCR-pMHC dissociation curves 
detected upon addition of imidazole at 15oC (t = 0) for CD8-null Jurkat T cells engineered with 
the indicated TCR variants (expressed as % of maximal binding over time) and labeled with 
wild-type NTAmers (monomer, blue circles) or CD8-binding deficient NTAmers227-228 
(monomer227-228, red circles). Decay of PE-NTA4 fluorescence (white circles) is also represented. 
Average dissociation half-life value (of 3 independent experiments) with wild-type NTAmers or 
NTAmers227-228 is shown for each TCR-transduced Jurkat T cell variant. (D) Positive correlations 
(Pearson coefficient r and p values) between surface-based monomeric half-lives (t1/2) with wild-
type NTAmer (monomer, blue line) or CD8-binding deficient NTAmer227-228 (monomer227-228, 
red line) on TCR-transduced CD8-null Jurkat T cells, and monomeric half-lives (t1/2) by SPR on 
soluble TCR variants. 
 
Figure 3. Relationship between cell-surface monomeric dissociation kinetics and calcium 
flux. (A-C) Intracellular calcium mobilization of CD8+ SUP-T1 cells expressing TCRs of 
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incremental affinities for pMHC before (baseline) and over time after stimulation with 1µg/ml 
A2/NY-ESO-1157-165-specific multimers (blue circles) or 1 µg/ml CD8-binding deficient A2/NY-
ESO-1157-165-specific multimers227-228 (red diamonds). A representative kinetic analysis of 
calcium mobilization is depicted in (A) and the mean calcium flux values of 4 independent 
experiments are plotted as Ca2+ peak MFI (x104) in (B) together with maximal calcium flux 
induced after ionomycin stimulation. (C) Correlation (Pearson coefficient r and p value) between 
calcium flux peak MFI and dissociation koff rates for SUP-T1 cells expressing TCRs within the 
physiological affinity range (blue circles). Calcium flux values for SUP-T1 cells expressing 
supraphysiological affinity TCRs (TMα, QMα and wtc51m) (blue stars), and those obtained 
after stimulation with CD8-binding deficient multimers227-228 (red diamonds) are shown, but 
were not included in the correlative analysis. (D) A representative kinetic analysis of calcium 
mobilization in primary TCR-transduced CD8+ T cells before (no antigen-presenting cells; APC) 
and after stimulation with T2 cells pulsed with graded concentration of the analog NY-ESO-1157-
165 peptide (SLLMWITQA) or ionomycin as positive control. (E) The mean calcium flux values 
were plotted as Ca2+ peak MFI with varying peptide concentration for each primary CD8+ TCR-
transduced T cell variant. No calcium flux was detected upon stimulation of wild-type (WT) NY-
ESO-1-transduced T cells with Flu-specific peptide (Flu) or no APCs. (F) Correlation (Pearson 
coefficient r and p value) between half-maximal calcium mobilization capacity (Ca2+ EC50) and 
NTAmer-based dissociation koff values for T cells expressing TCRs within the physiological 
affinity range (gray circles). Calcium flux values obtained for CD8+ T cells expressing TCRs of 
supraphysiological affinities (TMα, QMα and wtc51m) are shown (blue stars), but were not 
included in the correlative analysis. 
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Figure 4. Relationship between cell-surface monomeric dissociation kinetics and target cell 
killing. Experiments were performed on A2/NY-ESO-1157-165-specific CD8+ T cell clones (n = 
20) expressing eight well-defined TCRαβ clonotypes, derived from melanoma patient LAU 155 
as previously described (16). (A) Representative first-order monomeric dissociation curves 
obtained upon addition of imidazole at 4oC  (t = 0) for tumor-specific T cell clones stained with 
A2/NY-ESO-1157-165-specific-NTAmers. Average half-lives (t1/2) determined from each distinct 
TCRαβ clonotypes (n = 2 to 3 independent sister T cell clones) are indicated and were highly 
reproducible in two independent experiments (data not shown). (B) The relative functional 
avidity of tumor-specific T cell clones expressing distinct TCRαβ clonotypes was assessed by 
measuring their lytic capacity for T2 target cells (A2pos; TAPneg/neg) pulsed with graded 
concentration of the natural NY-ESO-1157-165 peptide (SLLMWITQC). (C) Correlations (Pearson 
coefficient r and p value) between relative functional avidity (EC50, peptide concentration used 
to achieve 50% of maximal lysis) and monomeric TCR-pMHC dissociation koff values. Mean 
EC50 values of 3 independent experiments. (D) Tumor reactivity by tumor-specific T cell 
clonotypes for the melanoma cell line Me275 (A2pos/NY-ESO-1157-165pos) at the indicated 
effector:target (E:T) ratio. (E) Correlations (Pearson coefficient r and p value) between 
melanoma cell killing (mean % of specific lysis at the E:T ratio of 10:1 from 2 independent 
experiments) and monomeric TCR-pMHC dissociation koff values. 
 
Figure 5. High-throughput screen of functionally relevant tumor-specific CD8+ T cells by 
NTAmers. Relationship between functional avidity and monomeric TCR-pMHC koff rates of a 
large panel of tumor-specific CD8+ T cell clones specific for A2/NY-ESO-1157-165 (A-C) or 
A2/Melan-AMART-126-35 (D-F) tumor antigen and derived from melanoma patient LAU 50 and 
 28 
  Hebeisen et al., v20150203 
LAU 618 respectively. (A, D) Representative first order dissociation curves obtained after 
addition of imidazole at 4oC for CD8+ A2/NY-ESO-1157-165-specific T cell clones (LAU 50; n = 
67) and A2/Melan-AMART-126-35-specific T cell clones (LAU 618, n = 80) respectively, stained 
with specific NTAmers and arbitrarily separated into short (white circles) or long (black squares) 
half-lives according to their t1/2 values. (B, E) Relative functional avidity on a selection of 
A2/NY-ESO-1157-165-specific T cell clones (n = 23) or A2/ Melan-AMART-126-35-specific T cell 
clones (n = 34) of short or long half-lives using T2 target cells pulsed with graded concentration 
of natural NY-ESO-1157-165- or Melan-AMART-126-35-specific peptide. (C, F) Positive correlations 
(Spearman coefficient r and p value) obtained between relative functional avidity by EC50 (50% 
of maximal target cell killing) and monomeric TCR-pMHC dissociation koff values. Each data-
point represents the result of an individual tumor-specific T cell clone, averaged from 2 
independent experiments. 
 29 
a0 600400
C
y5
-p
M
H
C
-- Fig. 1 --
200
c
Imidazole
100mM Time (s)
0 900600300
105
104
103
102
0
105
104
103
102
0
TMβwild type
P
E
-N
TA
4
Time (s)
Imidazole
 TCR-pMHC 
dissociation
Imidazole
NTAmer decay
b
60
120
240
0
Ti
m
e 
(s
)
V49I wild type DMβ
TMβ QMα wtc51m
TCR affinity
60
120
240
0
DIC PE Cy5 merged
10 μm
Time (s)
%
 m
ax
 b
in
di
ng
wild type
17.1 s
No TCR
N/A
G50A
47.0 s
A97L
44.2 s
V49I
3.3 s
TMα
158.3 s
DMβ
89.7 s
QMα
340.6 s wtc51m
1505 s
TMβ
247.3 s
d
Cy5 monomersPE NTA4

C
a2
+  p
ea
k 
(x
10
4 )
5
10
15
0
20
10-310-2100 10-4
r=0.72 
p=0.007
10-1
koff (s
-1) 
c
multimer
multimer227-228
C
a2
+ 
pe
ak
 (x
10
4 )
a
5
10
15
20
50
40
0
DM
β
TM
α
TM
β
V4
9I W
T
QM
α
wt
c5
1m
O
-- Fig. 3 --
G5
0A
A9
7L
multimer
Ionomycin
b
multimer227-228
Time (s)
0 100 200 300
5
10
15
20
25
0
5
10
15
20
25
0
C
a2
+ 
flu
x 
(x
10
4 )
100 200 300
TMβWT
QMα wtc51m
multimer227-228
multimer
Time (s)
20
30
0
C
a2
+ 
flu
x 
(x
10
4 )
0 300 600 900 1200
V49I
WT
TMβ10
20
30
0
10
20
30
0
10
no 
APC 10-11 10-9 10-8 10-7 5x10-6 iono10-6
d
C
a2
+ 
pe
ak
 (x
10
4 )
5
10
15
20
25
0
10-11 10-1010-9 10-8 10-7 10-6 10-5
peptide concentration (M) 
V49I
no APC
Flu ctl
WT
G50A
A97L
DMβ
TMβ
TMα
QMα
wtc51m
e f
C
a2
+  E
C
50
 (M
)
10-310-2100 10-410-1
r=0.98
p=0.0004
koff (s
-1) 
10-6
10-7
10-8
10-9


  Hebeisen et al. 
SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure S1. Determination of TCR-ligand off-rates on a panel of 
CD8+ T cells engineered with TCRs of incremental affinities against the A2/NY-
ESO-1 tumor antigen. (A and B) FACS-based TCR-pMHC dissociation curves for 
each TCR-transduced SUP-T1 cell variant are depicted after staining with wild-type 
HLA-A*0201/NY-ESO-1157-165 -specific NTAmers (A) or CD8 binding-deficient 
HLA-A*0201/ NY-ESO-1157-165 -specific NTAmers227-228 (B). Imidazole (100 mM) 
was added after 1 minute of baseline recording and monomeric pMHC dissociation 
was followed in the Cy5 channel during 10 to 15 minutes at constant temperature 
(15oC). (C) Monomeric TCR-pMHC dissociation rates, following reversible wild-
type NTAmer (monomer, blue circles) or CD8-binding-deficient NTAmer227-228 
(monomer227-228, red diamonds) staining, were analyzed in Prism and best fitted a first 
order monomeric decay function after subtraction of non-specific background. 
Average half-life values (in second, s) of > 3 independent experiments are depicted 
for each TCR-transduced SUP-T1 cell variant and were highly reproducible between 
two different investigators (data not shown). Of note, no NTAmer staining was 
detected in untransduced SUP-T1 cells (no TCR). N/A; not applicable.  
 
Supplementary Figure S2. Relationship between monomeric off-rates by 
reversible NTAmers and monomeric off-rates and affinity by SPR. (A) 
Correlations (Pearson coefficient r and p value) between surface-based TCR-pMHC 
off-rates (koff) with A2/NY-ESO-1157-165 -specific NTAmers (monomer, blue circles), 
CD8-binding deficient NTAmers227-228 (monomer227-228, red diamonds) or pure grade 
tetramers (white circles) on CD8+ TCR-transduced SUP-T1 cells, and monomeric 
off-rates (koff) (left panel) and affinities (equilibrium dissociation constant KD) (right 
panel) values as measured by SPR on soluble TCR variants. (B) Correlations (Pearson 
coefficient r and p value) between surface-based TCR-pMHC off-rates (koff) with 
A2/NY-ESO-1157-165 -specific NTAmers (monomer, blue circles) or CD8-binding 
deficient NTAmers227-228 (monomer227-228, red diamonds) on CD8- TCR-transduced 
Jurkat T cells, and monomeric off-rates (koff) and affinities (KD) values as measured 
by SPR on soluble TCR variants. Of note, similar correlations were obtained between 
NTAmers and NTAmers227-228 on TCR-transduced Jurkat T cells lacking CD8 
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expression (B) and were highly similar to those found by NTAmers227-228 on 
CD8+ SUP-T1 cells (A).  
 
Supplementary Figure S3. Monomeric dissociation half-lives of naturally 
occurring or vaccine-induced tumor-specific CD8+ T cell clones from three 
melanoma patients. (A) Representative examples of NTAmer-based dissociation 
kinetics of A2/NY-ESO-1157-165-specific CD8+ T cell clones expressing well-defined 
TCRαβ clonotypes isolated from melanoma patient LAU 155 as described in (1). (B) 
Representative examples of NTAmer-based dissociation kinetics of a large panel of 
A2/NY-ESO-1157-165 CD8+ T cell clones from melanoma patient LAU 50 with 
naturally occurring anti-tumor CD8+ T cell responses. (C) Representative examples 
of NTAmer-based dissociation kinetics of A2/Melan-AMART-126-35-specific CD8+ T 
cell clones from melanoma patient LAU 618 following Melan-AMART-126-35 peptide 
vaccination and CpG oligodeoxynucleotide 7909 as adjuvant. Imidazole was added 
after 1 minute (A) or 30 seconds (B and C) of baseline recording and monomeric 
dissociation was followed in the Cy5 channel at constant temperature (4oC) during 3 
to 5 minutes. (A-C) Data are expressed as % of maximal binding after subtraction of 
non-specific background, normalized to 100% and plotted over time (in seconds). 
Monomeric TCR-pMHC dissociation rates were analyzed in Prism and best fitted a 
first order monomeric decay function.  
 
Supplementary Figure S4. Monomeric TCR-pMHC kinetics of tumor-specific 
CD8+ T cell subpopulations according to the TRBV repertoire usage. NTAmer-
based dissociation half-lives were assessed on A2/NY-ESO-1157-165-specific CD8+ T 
cell clones derived from melanoma patient LAU 50 (n = 50) (A) and A2/Melan-
AMART-126-35-specific CD8+ T cell clones (n = 70) from melanoma patient LAU 618 
(B) and distributed according to the expression of TCR Vβ family usage by using 
anti-BV monoclonal antibodies (mAb) and flow cytometry. Of note, a convenient 
feature of the anti-BV13 and anti-BV17 mAb reactivity allowed us to clearly 
discriminate between bright/high and dim tumor-specific T cells. 
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Supplementary Figure S5. Impact of rapid association on-rates on cell surface 
dissociation kinetics by reversible NTAmers. Comparison of first order monomeric 
TCR-pMHC dissociation kinetics obtained with NY-ESO-1157-165-specific NTAmers 
(monomer, blue symbols) or CD8-binding deficient NTAmers227-228 (monomer227-228, 
red symbols) between two pairs of TCR variants among the panel of CD8+ SUP-T1 
cells, DMβ/TMα (top) and TMβ/QMα (bottom). These pairs express TCRs differing 
solely for αS53W, a TCR-alpha chain mutation known to significantly increase the 
association kon rates (TMα, 12.1x104 and QMα, 10.9x104 M-1s-1) while sharing 
similar dissociation koff rates by SPR(2) (see Table 1). The impact of αS53W 
mutation between each TCR pair on the dissociation half-lives by NTAmers and 
NTAmers227-228 is indicated as average fold difference from 3 independent 
experiments. Of note, rapid kon rates have been proposed to allow rapid rebinding of 
the TCR to the same pMHC without complete dissociation, thus prolonging effective 
dissociation half-lives when kon surpasses a threshold rate of 4.5 to 6x104 M-1s-1 as 
measured by SPR(3). This phenomenon of rapid rebinding is referred as the 
“confinement time” of a TCR-pMHC interaction and clarifies the role of kon in T cell 
activation(4). The differential experimental settings between NTAmer-based (cell 
surface of living cells) and molecular SPR-based measurements (plate bound with 
microflow system) may explain our observation that TCR variants with faster kon 
showed prolonged dissociation half-lives by NTAmers. Similar data were found when 
using CD8-binding deficient NTAmers227-228, suggesting that enhanced effective 
dissociation half-life is independent of the CD8-pMHC binding interaction. 
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